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BACKGROUND: Recently, preoperative chemoradiation therapy (CRT) for rectal cancer has been increasingly used as a neoadjuvant
treatment. In the present study, the relation between histological response to CRT and immunohistochemical markers in biopsy
specimens was investigated.
METHODS: Biopsy specimens from a total of 60 patients were collected before preoperative CRT with S-1 and irinotecan, and liniac
45Gy. Immunohistochemical staining for Ki67, Mcm3, Bax, Bcl-2, ssDNA, Grp78, thymidylate synthase (TS), dihydropyrimidine
dehydrogenase (DPD), CD34, vascular endothelial growth factor, nestin, and L-type amino-acid transporter 1 was performed to
allow comparison of the Ki67 labelling index (LI), Bax score, TS score, DPD score, microvessel density by CD34, and Grp78 score
with cancer regression.
RESULTS: When the cases were divided into responders (Dworak grades 3 and 4) and non-responders (grades 1 and 2) groups, good
correlations were evident with Ki67 LI, Bax, Grp78, and TS expression. On multiple logistic regression analysis, Ki67 LI, Bax, and TS
scores were found to be independent factors. With their use in a logistic model, P-values could predict responder cases with a
sensitivity of 82.8% and a specificity of 83.9%.
CONCLUSION: Using this system, treatment strategy for locally advanced rectal cancers can be determined before chemoradiation.
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Chemoradiation therapy (CRT) is increasingly used in neoadju-
vant approaches for rectal cancer. Although in locally advanced
cases there is generally no improvement of overall survival, local
control is better than with postoperative CRT (Sauer et al, 2004).
Combining irinotecan with 5-fluorouracil (5-FU) and leucovorin
(LV) chemotherapy can provide higher rates of tumour regression,
progression-free survival, and overall survival for metastatic
colorectal cancer (Saltz et al, 2000). Recently, our group has
developed a novel protocol for neoadjuvant CRT combining S-1
with irinotecan and radiation, allowing a complete pathological
response rate of 31.6% to be achieved (Sato et al, 2007). It is well
established that a pathological complete response (CR) or near CR
(495% pathological response) is significantly linked with
improved patient survival (Ruo et al, 2002; Guillem et al, 2005).
S-1 is a novel oral fluoropyrimidine, combining tegafur (FT),
5-chloro-2,4-dihydroxypyridine (gimeracil or CDHP), and potas-
sium oxonate (oteracil potassium or Oxo). FT is a prodrug for
5-FU that acts as an effector. CDHP reversibly inhibits the
degradation of 5-FU by dihydropyrimidine dehydrogenase (DPD),
resulting in prolonged high concentrations of 5-FU in the blood
(Sato et al, 2007). Irinotecan (CPT-11) inactivates topoisomerase I
through the formation of stable topoisomerase I–DNA cleavable
complexes (Hsiang et al, 1985; Hsiang and Liu, 1988; Hertzberg
et al, 1989). Interaction of the trapped cleavable complex with a
replication fork results in replication arrest and fork breakage,
finally leading to cell death (D’Arpa and Liu, 1989).
High proliferative activity examined with Ki67 and proliferating
cell nuclear antigen (PCNA) staining (Willett et al, 1995), high Bax
expression (Chang et al, 2005), and high thymidylate synthase (TS)
(Negri et al, 2008) have been demonstrated to predict regression.
However, these factors have been treated as univariate factors. No
clinically applicable system for prediction of response of CRT has
been proposed. We therefore have investigated cell proliferation,
apoptosis, apoptosis-associated protein, expression of glucose-
regulated protein 78 (Grp78), TS, DPD, and angiogenesis in biopsy
samples in an attempt to develop a predictive system. Selection of
these parameters was for the following reasons.
Thymidylate synthase provides de novo thymidylate for
DNA synthesis, catalysing the methylation of deoxyuridine
monophosphate to deoxythymidine monophosphate (Danenberg,
1977). The activity of 5-FU mainly depends on intracellular
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sconversion to its active metabolite, 5-fluoro-20-deoxyuridine-50-
monophosphate, which inhibits DNA synthesis by forming a stable
complex with TS in presence of folates (Pinedo and Peters, 1988),
and then initiates cell-cycle arrest or cell death. In general, high
expression of thymidine phosphorylase and low expression of DPD
in tumours are considered to result in higher intratumoural
concentration of 5-FU (Jakob et al, 2005).
Glucose-regulated protein 78 is a member of the Hsp70
superfamily of heat-shock proteins whose increased expression is
part of a coordinated protein response required to alleviate
endoplasmic reticulum stress (Misra et al, 2005), maintain
endoplasmic reticulum function, and protect cells against cell
death. Glucose-regulated protein 78 may confer resistance against
adriamycin- and etoposide-mediated apoptosis in cancer cells
through inhibition of Bax and caspase-7 activation (Reddy et al,
2003; Davidson et al, 2005; Ermakova et al, 2006; Lee et al, 2006;
Ranganathan et al, 2006).
Recently, the concept of cancer stem cells has attracted
increasing attention with regard to human cancers (Wang and
Dick, 2005). Minichromosome maintenance (Mcm) proteins 2–7
are present through all phases of the proliferative cell cycle, but are
absent in ‘out-of-cycle’ states, suggesting functions as replication
licensing factors (Stoeber et al, 2001), and Dudderidge et al (2005)
have proposed that the Mcm2-Ki67 labelling index (LI) reflects the
presence of non-proliferating dormant ‘cancer stem’ cells,
associated with reduced disease-free survival in renal cell
carcinoma cases.
It was reported that high intratumoural microvessel density
(MVD) and vascular endothelial growth factor (VEGF) were
correlated with poor prognosis of colorectal cancer (Des Guetz
et al, 2006). It has been also reported that VEGF-positive rectal
cancer was resistant to radiotherapy (Zlobec et al, 2008). Nestin, a
class VI intermediate filament protein, has recently received
attention as a marker for detecting newly formed endothelial cells
(Teranishi et al, 2007).
As for apoptosis, cancer cell apoptosis in biopsy before CRT was
correlated with tumour regression whereas apoptosis inhibitory
protein Bcl-2 expression indicated no correlation with regression
(Ro ¨del et al, 2002). In addition, L-type amino-acid transporter 1
(LAT1) is highly expressed in malignant tumours to support
growth and proliferation, and the inhibition of LAT1 activity led to
cancer cell apoptosis (Kim et al, 2008).
Using these parameters, multiple logistic regression analysis
was adopted to generate a model for predicting response to pre-
operative CRT.
MATERIALS AND METHODS
A total of 60 cases of rectal cancer treated with preoperative CRT
were collected. The patients’ clinical criteria were previously
reported (Sato et al, 2007). Briefly, all had previously untreated
locally advanced distal rectal cancer T3 or T4, N0-2, and M0 (UICC
classification) (Sobin and Wittekind, 2002), with an Eastern
Cooperative Oncology Group performance status of 0-2 (Oken
et al, 1982). Ages were 20–80 years at enrolment.
Biopsy materials of the 60 cases were endoscopically obtained
from the rectal cancers before the initiation of therapy, at least two
pieces of carcinoma being sampled for each case. The histological
typing was in accordance with the WHO classification (Hamilton
and Aaltonen, 2000). Tumour size was measured using double-
contrast barium enema in 56 cases, but no X-ray photographs were
available for 4 cases. Clinical tumour node metastasis (TNM) stage
was judged with computed tomographic scans and/or magnetic
resonance images. Because images were not available for two cases,
clinical TNM stage could not be determined for these. A summary
of clinical data of the cases is shown in Table 1. All patients
received preoperative chemoradiation as follows: radiotherapy was
administered in liniac fractions of 1.8Gy per day, 5 days per week.
The total dose of radiation was 45Gy. S-1 (80mgm
 2 per day) and
was given orally after breakfast and dinner on days 1–5, 8–12,
22–26, and 29–33. Irinotecan (80mgm
 2) was administered as a
continuous i.v. infusion for 90min on days 0, 8, 22, and 29. Radical
surgery was performed at least 4–6 weeks after the completion of
5 weeks of chemoradiation. The dose of S-1 was in accordance
with the manufacturer’s guideline (Taiho Pharmaceuticals Co. Ltd,
Tokyo, Japan). The recommended dose of irinotecan was
examined in our previous study (Sato et al, 2007). This protocol
was started in 2004 with approval of the ethics committee of
Kitasato University Hospital. All patients gave written informed
consent.
Pathological evaluation
Therapeutic responses to preoperative CRT were evaluated with
the surgically resected specimens. The excised tissues were fixed in
buffered formalin and embedded in paraffin. In each case, the
entire lesion was serially sliced at 4mm for routine processing and
embedding in paraffin. Then, 4-mm-thick sections were cut, stained
with haematoxylin and eosin, and examined by light microscopy.
Amounts of residual tumour mass, fibrotic changes, radiation
vasculopathy, and peritumoural inflammatory reaction were
checked, and therapeutic effects were assessed using Dworak
grades (Dworak et al, 1997) as follows:
grade 0: no regression;
grade 1: dominant tumour mass with obvious fibrosis and/or
vasculopathy;
grade 2: dominant fibrotic changes with few tumour cells or
groups (easy to find);
grade 3: very few tumour cells in fibrotic tissue with or without
mucous substance;
grade 4: no tumour cells, only fibrotic mass (total regression).
Immunohistochemistry of Ki67, Mcm3, Bax, Bcl-2, ssDNA,
Grp78, TS, DPD, CD34, VEGF, nestin, and LAT1
Formalin fixed, paraffin-embedded histological sections (4mmi n
thickness) in tumour biopsies before CRT were immunostained for
12 antigens (Ki67, Mcm3, Bax, Bcl-2, ssDNA, Grp78, TS, DPD,
CD34, VEGF, nestin, and LAT1). The antibodies used and methods
Table 1 Characteristics of the patients
Characteristic
Age (year) (mean±s.d.) (n¼60) 63.9±10.6 (range 32–81)
Sex (male/female) (n¼60) 44 (73.3%)/16 (26.7%)
Tumour size (mm) (mean±s.d.) (n¼56) 47.4±17.2 (range 20–95)
Clinical T stage (n¼58)
cT3 56
cT4 2
Clinical N stage (n¼58)
cN0 32
cN1/cN2 26
Histological type (biopsy) (n¼60)
Well 36
Moderate 23
Poor 1
CEA (mg/100ml) (mean±s.d.) (n¼60) 8.9±12.7
CA19-9 (ng/ml) (mean±s.d.) (n¼60) 19.7±27.2
s.d., standard deviation. Normal ranges of CEA and CA19-9 were o5mg/100mland
o37ng/ml, respectively. Tumour size (based on double-contrast barium enema), clinical
TN stage, and tumour markers were evaluated before chemoradiation therapy.
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sfor antigen retrieval are listed in Table 2. Endogenous peroxidase
was blocked with 3.0% hydrogen peroxide for 10min, and
incubation with Protein block serum-free solution (DakoCyto-
mation, Glostrup, Denmark) for 10min. Sections were incubated
with the anti-Ki67, Bax, Grp78, TS, DPD, and CD34 primary
antibodies for 60min at room temperature, and with the anti-
Mcm3, Bcl-2, ssDNA, VEGF, and nestin antibodies overnight at
41C. After incubation with either labelled polymer, anti-mouse, or
anti-rabbit (EnVisionþ System HPR; DakoCytomation) for
60min at room temperature, 3,30-diaminobenzidine was used as
the chromogen. Nuclei were counterstained with methyl green
solution to facilitate histopathological assessment. The immuno-
histochemical protocol with the LAT1 staining kit (Fuji Biomedix,
Tokyo, Japan) was according to the manufacturer’s manual.
Evaluation of immunohistochemical staining
Ki67 and Mcm3 LI were determined as percentage values counting
at least 1000 tumour cells in high-power fields ( 400). With
ssDNA staining, immunohistochemically positive cells were so few
in number that at least 5000 nuclei were counted. ssDNA indices
also were determined as percentage values.
Immunoreactivity for Bax, Bcl-2, Grp78, TS, DPD, and VEGF
was evaluated using a score based on the classification of Sinicrope
et al (1995). The staining intensity was scored as follows: none, 0;
weak, 1; moderate, 2; intense, 3. If heterogeneity of staining
intensity existed in a section, the staining intensity was scored
based on that which was predominantly observed. The percentages
of positive cells were assigned to one of five categories of protein
expression: 0, p5%; 1, 5–25%; 2, 25–50%; 3, 50–75%; 4, X75%.
The two scores were then multiplied to produce a weighted score
for each tumour specimen. Two pathologists (MK and TM)
independently scored the lesions and determined the final scores
by discussion when they differed.
CD34-expressing capillaries were counted to give the MVD.
Nestin-examined capillaries were considered as capillaries con-
sisting of newly formed endothelial cells (Teranishi et al, 2007).
Areas of highest neovascularisation were found by scanning
tumour sections at low power ( 100). The highest vascular
counts of two different fields were averaged and used to calculate
numbers of microvessels per mm
2, defined as MVD with both
stainings.
For LAT1, a biomarker for high-grade malignancy, staining
intensity was scored according to a previous report (Sakata et al,
2009): none, 0; weak, 1; moderate, 2; intense, 3. The percentages of
positive cells were assigned to one of four categories: 0, o0%; 1,
1–10%; 2, 10–30%; 3, 430%. The values for the two variables
were then multiplied, resulting in a scoring from 0 to 9. Two
pathologists (MK and TM) independently scored the lesions.
Statistical analysis
Data were analysed using Dr. SPSS II (SPSS, Chicago, IL, USA) and
Statview 5.0 (SAS Institute Inc., Cary, NC, USA) software.
Immunohistochemical labelling and scores were compared using
the Kruskal–Wallis test and the Mann–Whitney U-test. Logistic
regression analysis was performed with a stepwise method.
Po0.05 was considered as statistically significant.
RESULTS
Pathological response to CRT
Pathological evaluation of responses to preoperative CRT in
resected rectum revealed radiation effects in all cases, with fibrosis
and vascular changes. All 60 cases were classified into Dworak
regression grades 1–4. Of these, 15 (25.0%) showed complete
pathological responses (regression grade 4) and 14 (23.3%) showed
microscopic residual tumours (regression grade 3), whereas 21
(35.0%) and 10 (16.7%) showed moderate (regression grade 2) or
minimal (regression grade 1) responses to preoperative CRT,
respectively.
Ki67, Mcm3, and ssDNA expression was confined to tumour cell
nuclei, and Bax, Bcl-2, Grp78, and VEGF immunoreactivity to the
tumour cell cytoplasm. TS and DPD were expressed in both nuclei
and cytoplasm. LAT1 was confined to cell membranes, and CD34
and nestin were expressed in endothelium of intratumoural
microvessels (Figure 1).
Figure 2 demonstrates the relationship between each immuno-
histochemical marker of the tumour biopsies before CRT and the
pathological tumour response. A high Ki67 LI, Bax score, TS score,
DPD score, MVD by CD34, and a low Grp78 score correlated with
regression on univariate analysis. Recent studies have revealed that
Table 2 Antibodies used for the immunohistochemical study
Antibody Clone Source Dilution Antigen retrieval
Ki67 Monoclonal MIB-1 DakoCytomation, Glostrup, Denmark 1:50 Treatment in hot bath (95–981C)
for 40min (Dako Target Retrieval Solution (pH 9.0))
Mcm3 Monoclonal 3A2 MBL, Nagoya, Japan 1:400 Microwave treatment for 15min
(Dako Target Retrieval Solution (pH 9.0))
Bax Monoclonal B-9 Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA
1:100 Microwave treatment for 15min
(citrate buffer (pH 6.0, 0.01mol/l))
Bcl-2 Monoclonal 124 DakoCytomation 1:50 Microwave treatment for 15min
(Dako Target Retrieval Solution (pH 9.0))
ssDNA Polyclonal A4506 DakoCytomation 1:400 Not applied
Grp78 Polyclonal H-129 Santa Cruz Biotechnology, Inc. 1:100 Microwave treatment for 30min
(citrate buffer (pH 6.0, 0.01mol/l))
TS Monoclonal TS106 DakoCytomation 1:50 Autoclave (1211C) treatment
for 15min (citrate buffer (pH 6.0, 0.01mol/l))
DPD Polyclonal RDPDPA Taiho Pharmaceuticals Co., Ltd.,
Tokyo, Japan
1:400 Autoclave (1211C) treatment for 10min
(EDTA (pH 8.0, 1mmol/l))
CD34 Monoclonal QBEnd 10 DakoCytomation 1:500 Not applied
VEGF Polyclonal A-20 Santa Cruz Biotechnology, Inc. 1:100 Not applied
Nestin Polyclonal N1602 IBL, Takasaki, Japan 1:500 Not applied
LAT1 Monoclonal Fuji Biomedix, Tokyo, Japan Prediluted Microwave treatment for 5min
(in the buffer supplied by kit)
Mcm, minichromosome maintenance; Grp78, glucose-regulated protein 78; TS, thymidylate synthase; DPD, dihydropyrimidine dehydrogenase; VEGF, vascular endothelial growth
factor; LAT1, L-type amino-acid transporter 1.
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spathological CR and greater than 95% pathological response
groups achieve a significantly improved overall survival and
recurrence-free survival when compared with less than 95%
pathological response groups (Ruo et al, 2002; Guillem et al,
2005). Therefore, we divided the cases into two groups: Dworak
grades 1 and 2, and grades 3 and 4 (Gavioli et al, 2005). The latter
were considered as responders to CRT. A high Ki67, Bax score, and
TS score and a low Grp78 score were well correlated with
response. On the other hand, there were no associations with the
other immunohistochemical factors, as well as clinicopathological
factors (Table 3).
Multiple logistic regression analysis
Multiple logistic regression analysis was performed with a stepwise
method (Tanaka et al, 1999). Independent variables were the data
for Ki67 LI, Bax score, TS score, and Grp78 score, and dependent
variables were no-response (0; Dworak regression grades 1 and 2)
or response (1; Dworak regression grades 3 and 4). Other
immunohistochemical markers and clinicopathological factors
were not used. By the logistic regression analysis, we detected
the Ki67 LI, Bax score, and TS score as independent factors
(Table 4). The Bax score (odds ratio 18.1) had the strongest
influence. The logistic regression formula was as follows:
loge ðp=1   pÞ¼  24 þ 0:15 ½Ki67 LI þ2:90
 ½Baxscore þ0:60 ½TSscore :
Receiver-operating characteristic curve
A receiver-operating characteristic curve was generated by plot-
ting the true-positive rate (sensitivity) on the y axis and the
AB
CD
EF
Figure 1 Immunohistochemical staining of pre-treatment rectal biopsy specimens from locally advanced rectal cancers. (A) Ki67 immunoreactivity,
(B) Bax immunoreactivity, (C) Grp78 immunoreactivity, (D) TS immunoreactivity, (E) DPD immunoreactivity, and (F) CD34 immunoreactivity. Note Ki67
immunoreactivity confined to the tumour cell nuclei, Bax, and Grp78 to the tumour cell cytoplasm, TS and DPD to the tumour cell nucleus and cytoplasm,
and CD34 to the endothelium of intratumoural microvessels.
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sfalse-positive rate (1 specificity) on the x axis (Figure 3) (Tanaka
et al, 1999).
Although the P-value at the point closest to the left upper corner
on the curve is generally considered to represent the best balance
of both sensitivity and specificity in distinguishing between
response and no-response, we determined four points of P as the
cut-off values (0.90, 0.50, 0.40, and 0.20) to construct practical
criteria for the five categories ‘responder’, ‘probable responder’,
‘unknown’, ‘probable non-responder’, and ‘non-responder’
(Table 5). The points of P¼0.90 and 0.20 meant the points of
specificity 100% and sensitivity 100%, respectively. The point of
P¼0.50 meant the point at which the specificity was maximum
and the sensitivity was more than 80%. The point of P¼0.40
meant the point at which the specificity for prediction of non-
responder was maximum and the sensitivity more than 80%.
Sensitivity and specificity
A P-value for each case was calculated with three immunohisto-
chemical markers examined in 60 sets of biopsy specimens. Using
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Figure 2 Ki67, Bax, Grp78, TS, DPD, and CD34 (MVD) were significantly related to chemoradiosensitivity (Po0.05). High Ki67 LI, Bax score, TS score,
and low Grp78 were significantly correlated with tumour regression when responders were defined as having Dworak regression grades 3 and 4.
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sthe calculated P-value, we classified the 60 patients into one of
the above five categories with criteria distinguishing between
responder and non-responder. Sensitivities and specificities of the
criteria are shown in Table 5.
DISCUSSION
In this study, we sought clinicopathological factors and immuno-
histochemical markers that might contribute to prediction of
chemoradiation effects on locally advanced rectal cancer. Our
conclusion is that it is possible to predict a responder to
preoperative CRT, with 82.8% sensitivity and 83.9% specificity,
using the value calculated with the three elements of the Ki67 LI,
the Bax score, and the TS score in biopsy specimens before CRT. In
fact, high expression of Ki67, Bax, and TS was positively correlated
with therapeutic effects.
The first factor, high proliferative activity with Ki67 as the
marker, was earlier found to correlate with PCNA immunostain-
ing, and mitotic counts after radiation of rectal cancer (Willett
et al, 1995). Later, beneficial effects of radiotherapy for patients
with various carcinoma with high Ki67 LIs were reported (Nakano
et al, 1997; Raybaud-Diogene et al, 1997). However, in other
reports, no relation was noted between Ki67 values in biopsy
specimens before radiation and response rate in rectal cancers
(Suzuki et al, 2004; Debucquoy et al, 2008). Suzuki et al (2004)
performed preoperative radiotherapy only. Debucquoy et al (2008)
combined preoperative radiotherapy and/or 5-FU/LV. Because we
adopted CRT for all patients, the response may be more influenced
by chemotherapy than radiation.
The second factor, Bax expression, was also reported by Chang
et al (2005) to correlate well with chemoradiation therapeutic
effects, and the authors considered that apoptosis may be
important in rectal carcinoma response to CRT. Similarly, Bax
overexpression has been found to correlate with anticancer drug
sensitivity in a variety of human cancers, through enhanced
induction of apoptosis (Krajewski et al, 1995; Guo et al, 2000;
Teranishi et al, 2007). However, Gosens et al (2008) did not find
any link between Bax expression and rectal cancer regression for
neoadjuvant chemoradiation. They evaluated the regression
grading system described by Ro ¨del et al (2005): (1) no regression
or o25% of tumour mass, (2) 25 to 450% tumour regression, and
Table 3 Clinicopathological characteristics of the patients separated by
Dworak grades 1, 2 vs 3, 4
Dworak
grade 3, 4
(responder)
(n¼29)
Dworak
grade 1, 2
(non-responder)
(n¼31)
Age (year) (mean±s.d.) 63.5±11.4 63.5±9.8 P¼0.11
Sex
Male 21 24
Female 8 7 P¼0.65
Tumor size (mm)
(mean±s.d.)
46.7±14.4 48.0±19.7 P¼0.98
Histological type (biopsy)
Well 17 20
mod/por 12 11 P¼0.64
CEA (mg/100ml)
(mean±s.d.)
8.5±12.7 9.4±8.5 P¼0.23
CA19-9 (ng/ml)
(mean±s.d.)
17±25 22±29 P¼0.054
Well, well-differentiated adenocarcinoma; mod/por, moderately to poorly differ-
entiated adenocarcinoma; s.d., standard deviation.
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Figure 3 Receiver-operating characteristic curve with the logistic
regression model. The area under the curve is 0.928 (95% confidence
interval; 0.867–0.988).
Table 5 Criteria for Dworak grades 1, 2 vs 3, 4, and their validities tested among the 60 patients
Pathological response Validity
DG 3, 4 DG1, 2 DG 3, 4 DG 1, 2
Category Definition (P) Definition (P) Responder (n¼29) Non-responder (n¼31) Se Sp Se Sp
Responder 0.90pP 2.20pP 13 0 44.8 100
Probable responder 0.50pPo0.90 0pPo2.20 11 5 82.8 83.9
Unknown 0.40pPo0.50  0.41oPo01 1
Probable no-responder 0.20oPp0.40  1.39oPp 0.41 4 7 80.6 86.2
No-responder Pp0.20 Pp 1.39 0 18 58.1 100
P, probability; DG, Dworak grade; Se, sensitivity; Sp, specificity; P¼loge (P/1 P).
Table 4 Results of multiple logistic regression analysis
Regression coefficient P-value Odds ratio 95% CI
Variable
Ki67 LI 0.15 0.002 1.17 1.06–1.29
Bax score 2.90 0.001 18.1 3.11–105.7
TS score 0.60 0.019 1.83 1.11–3.03
Constant  24.47 o0.001
LI, labelling index; CI, confidence interval.
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s(3) complete regression. In addition, Bax immunohistochemical
values were only intensity of cytoplasmic staining 0–3. Differences
in grading systems and immunohistochemical expression scoring
could clearly influence the results.
Rau et al (2003) immunohistochemically investigated the
expression of p53, Bax, p21, Ki67, hMSH2 in pre- and post-
therapeutic rectal carcinoma with preoperative radiotherapy. Only
low p21 expression in tumour samples was significant in no-
response to neoadjuvant chemoradiation. They reported no
relation with Bax expression but classified responders as CR or
partial response, histopathologically defined with resected post-
therapeutic rectum, again differing from our definition as Dworak
grades 3 or 4.
The third factor, TS, is important in pyrimidine nucleotide
synthesis and represents an important chemotherapeutic target for
5-FU chemotherapy. Immunohistochemically, high TS expression
in pre-treatment locally advanced rectal cancer biopsies was earlier
shown to be predictive of a higher pathological response in the
fluorouracil/oxaliplatin-base chemotherapy (Negri et al, 2008).
A trend toward a direct correlation between the level of TS
expression and response of 5-FU/LV treatment in patients with
metastatic colon cancer has been noted (Johnston et al, 2003).
Similar results have also been reported by Edler et al (2002) and
Kornmann et al (2003).
However, low TS expression was a predictor of response to 5-FU
chemotherapy for colorectal cancer metastases (Aschele et al,
1999) and advanced colorectal cancer (Cascinu et al, 1999).
Aschele et al (1999) used a regimen of schedule-specific
biochemical modulation of 5-FU plus methotrexate, and Cascinu
et al (1999) applied 5-FU/LV. In both studies, cases with
metastases and/or recurrence were included, and TS expression
was evaluated as intensity 0 (undetectable staining) to 4 (very high
intensity of staining), and then intensity levels 0–2 were
considered as low, and 3 and 4 as high expression. We examined
both cytoplasmic TS expression intensity and percentage of
positive cells, as well as the Bax value. In another study, by
Liersch et al (2006), TS expression was examined in surgically
resected rectal cancer. In the reports, high TS expression
correlated with cancer relapse. The clinical meaning of evaluation
of TS expression needs further clarification.
The multiple logistic regression analysis revealed Ki67 LI, Bax
score, and TS score to be independent factors, with a sensitivity
and specificity for prediction of responder cases of 82.8 and 83.9%,
respectively. Although the logarithm model is difficult to calculate
for daily use, it can be easily converted to a linear model. It is
sufficient for users to know the values of loge (P/1 P) at the point
of criteria. Practically, users can directly substitute the Ki67 LI, Bax
score, and TS score into the formula:
Y
¼ logeðp=1   pÞ¼  24 þ 0:15 ½Ki67LI þ2:90
 ½Baxscore þ0:60 ½TSscore :
If this value P (loge (P/1 P)) is larger than 0.00, it indicates a
responder case. If it is smaller than  0.41, it indicates a non-
responder case (Table 5).
At present, CRT with subsequent surgical resection is performed
without selection of cases. However, with our approach, likely
responder cases can be chosen before therapy. In the future, our
multivariate model should be revised using new factors to improve
the sensitivity and specificity. The treatment strategy for locally
advanced rectal cancer should be further developed toward so-
called tailor-made therapy including such evaluation before
preoperative therapy and/or surgical resection.
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